登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>Nectin-4 >NE4-M82E7

Biotinylated Mouse Nectin-4 Protein, His,Avitag™ (MALS verified)

分子别名(Synonym)

NECTIN4,LNIR, PRR4, PVRL4

表达区间及表达系统(Source)

Biotinylated Mouse Nectin-4 Protein, His,Avitag (NE4-M82E7) is expressed from human 293 cells (HEK293). It contains AA Gly 31 - Ser 347 (Accession # Q8R007-1).

Predicted N-terminus: Gly 31

Request for sequence

蛋白结构(Molecular Characterization)

Nectin-4 Structure

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™)

The protein has a calculated MW of 37.9 kDa. The protein migrates as 43-48 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

标记(Labeling)

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

蛋白标记度(Protein Ratio)

Passed as determined by the HABA assay / binding ELISA.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>90% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

Nectin-4 SDS-PAGE

Biotinylated Mouse Nectin-4 Protein, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

SEC-MALS

Nectin-4 SEC-MALS

The purity of Biotinylated Mouse Nectin-4 Protein, His,Avitag (Cat. No. NE4-M82E7) is more than 90% and the molecular weight of this protein is around 35-50 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-ELISA

Nectin-4 ELISA

Immobilized Biotinylated Mouse Nectin-4 Protein, His,Avitag (Cat. No. NE4-M82E7) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human Nectin-1, Fc Tag (Cat. No. PV1-H5253) with a linear range of 0.1-2 ng/mL (QC tested).

Protocol

 
评论(0)
 
ACRO质量管理体系
 
 

背景(Background)

Nectin-4(Nectin cell adhesion molecule 4) is a Nectin and nectin-like family of cell adhesion molecules. It is found in high levels in normal embryonic and fetal tissues, but decreases after adulthood and is limited in distribution in healthy tissues. Nectin-4 is overexpressed in a variety of tumor cells and promotes tumor cell growth and proliferation. Solid tumors with high expression of Nectin-4 include bladder cancer, pancreatic cancer, triple negative breast cancer, non-small cell lung cancer, stomach cancer, esophageal cancer, ovarian cancer and many other cancers. Studies have found that Nectin-4 promotes tumor cell proliferation, differentiation, migration and invasion by activating the PI3K/Akt pathway, and is believed to play an important role in the occurrence and metastasis of cancer. It is based on these research backgrounds that drug research targeting this target has emerged.

 

前沿进展

Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancer
Sternschuss, Rosenberg
Future Oncol (2025)
Abstract: Combination treatment with Enfortumab vedotin (EV), an antibody drug conjugate targeting Nectin-4 with a monomethyl auristatin E (MMAE) payload, and pembrolizumab, a programmed death 1 (PD-1) inhibitor, has become the new standard of care for previously untreated locally advanced or metastatic urothelial carcinoma. In the recently published phase III study, EV-302, EV and pembrolizumab demonstrated improved outcomes compared to platinum-based chemotherapy, including objective response rate, progression free survival, and an unprecedented median overall survival of 33.8 months (versus 15.9 months; hazard ratio for death 0.51; 95% confidence interval 0.43-0.61; p < 0.00001). We reviewed the mechanism of action, clinical efficacy, exploratory biomarkers, and safety profile of EV and pembrolizumab as monotherapies and combination in urothelial cancer.
Theranostic implications of Nectin-4 oncoprotein in gynecologic cancers: A review
Hooks, Nagpal, Childers et al
Pathol Res Pract (2025) 269, 155913
Abstract: Gynecologic cancers, in order of prevalence, include uterine, ovarian, cervical, vaginal, and vulvar cancers. In 2024, there will be more than 116,000 new cases of gynecologic cancers and 33,800 disease-related deaths. Therefore, a concerted effort has been made to better understand the underlying pathophysiological processes and identify novel theranostic approaches.Comprehensively examine the current peer-reviewed literature surrounding Nectin-4 and its implication in the identification and treatment of gynecologic cancers.PubMed and Google search with relevant keywords for articles published in the last 15 years.Nectin-4 as a cell adhesion molecule (CAM) promotes cell growth through intra-tumoral angiogenesis, strengthens cell-cell bonds, and creates a tight spheroid structure, which is more chemotherapy resistant. In high-grade serous ovarian cancer (HGSOC), Nectin-4 is strongly associated with the presence of peritoneal metastases and worse prognoses. When compared to CA-125, a common tumor marker for ovarian cancer, Nectin-4 showed higher specificity and sensitivity for predictive value of tumorigenesis. Regarding cervical cancer, inhibition of Nectin-4 by nanoformulated Quinacrine inhibits both cancer stem cell proliferation and DNA damage. Nectin-4 as a tumor marker can discriminate endometrial cancer from healthy adjacent tissue with a specificity of 95.4 % and sensitivity of 82.81 %. Lastly, there is scarce evidence of Nectin-4 and fallopian tube, vaginal, or vulvar cancer but given ovarian cancer cells may originate from the fallopian tube, there is plausibility of using Nectin-4 to detect fallopian and/or ovarian cancer earlier.Overall, Nectin-4 as a promoter of cancer cell growth and metastasis supports the emphasis in current peer-reviewed literature as an effective theranostic biomarker.Copyright © 2025 Elsevier GmbH. All rights reserved.
A Peptide Derived from Nectin-4 Increases Cisplatin Cytotoxicity in Cell Lines and Cells from Ovarian Cancer Patients' Ascites
Boylan, Walz, Schefter et al
Cancers (Basel) (2025) 17 (5)
Abstract: New approaches to the treatment of women with ovarian cancer are desperately needed, since most women develop resistance to chemotherapy and the 5-year survival rate remains low. The hypothesis guiding this study was that the inhibition of cell adhesion could be used as a novel strategy to increase the chemosensitivity of ovarian cancer cells.The Nectin-4 peptide N4-P10 was used to inhibit the formation of cell-cell aggregates (spheroids) using cell lines and cells isolated from ovarian cancer patients' ascites. Cell lines were pre-treated with peptide N4-P10 or control scrambled peptides and monitored for spheroid formation with live-cell imaging by digital time-lapse photography. Cells were then tested for the cytotoxicity of the chemotherapeutic agent, cisplatin.Peptide N4-P10 blocked aggregation in cell lines with different levels of Nectin-4 expression and different spheroid morphologies. The cytotoxicity of cisplatin increased in cells pre-treated with peptide N4-P10. Similarly, when single cells were isolated from the ascites of ovarian cancer patients, peptide N4-P10 blocked cell aggregation and increased the cytotoxicity of cisplatin.These results suggest that targeting the cell-cell adhesive property of cancer cells could serve as a new approach to augment the cytotoxic effect of chemotherapy and potentially reduce disease recurrence in ovarian cancer patients.
Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies
Jiang, Xu, He et al
Front Pharmacol (2025) 16, 1525733
Abstract: Antibody-drug conjugates (ADCs) play an important role in the targeted therapy of gynecological malignancies. The purpose of this study was to investigate the expression of targets in gynecologic malignancies in order to predict the selection of targets for the development of antibody-drug conjugates.In this article, we identified existing ADCs and their targets through clinical trial databases and public genomic datasets, performed differential analysis of tumor antigen targets (TATs) expression between tumor and normal tissues, and evaluated the necessity of the targets for tumor cell lines.In gynecologic malignancies, we have identified several highly expressed TATs, some of which have been targeted by FDA-approved ADCs, such as TROP2 and Nectin-4, although these drugs have not been approved for the treatment of gynecologic cancers. At the same time, we also observed that some targets of ADCs that have not yet been approved by the FDA also show high expression levels in gynecologic malignancies tissues, such as MSLN, ERBB3, NaPi2b, etc. Furthermore, we identified TATs with high expression levels in various pathological subtypes of ovarian, endometrial, and cervical cancer. Notably, some TATs are crucial to the survival of tumor cells, such as CD71, TOP1, and TDGF1, which are essential for the survival of ovarian, endometrial, cervical, and other tumor cells.We have innovatively predicted the potential targets of ADCs in treating gynecological malignancies and provided a new perspective on applying some FDA-approved ADCs in indications for gynecological cancers.Copyright © 2025 Jiang, Xu, He, Sui, Li, Xia and Yao.
Showing 1-4 of 414 papers.
Powered by BizGenius
 
 
货号/价格
产品推荐
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
Nectin-4靶点信息
英文全称:Nectin-4
中文全称:细胞黏附分子nectin-4
种类:Homo sapiens
上市药物数量:1详情
临床药物数量:14详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定